提供支持Yaohai Bio, a genetic engineering protein drug developer, announced that it has completed a series B equity financing of more than 100 million yuan. The investors are Hetang Venture Capital (Tuesday Venture Capital), Hangzhou Saiying, and Shengshi Jincai.
This round of financing will be mainly used for capacity expansion, and the total construction area of the expansion project is about 10,000 square meters.
After the completion of the project, three liquid production lines, one pre-filling production line, a modern quality inspection and research center, and a professional CDO service center will be added. By then, the total scale of Yaohai Biological Fermentation will reach 5100L, and it can provide CDMO services of 10L-100L, 500L, 1000L and 2000L. At the same time, it can provide 10 million vials of vials, freeze-dried powder injections, and pre-filled vials. CDMO service for packaging preparations; it can meet the needs of biopharmaceutical process development, clinical sample preparation, and commercial production registered in China, the United States and the European Union.
Jiangsu Yaohai Biopharmaceutical Co., Ltd. was established in August 2010. Since 2016, it has been engaged in microbial expression system CDMO services. After completing the A round of financing in March 2019, it will focus more on the biopharmaceutical contract R&D and production service market.
The company has passed four years With the efforts of the company, the service project covers pre-clinical process research and sample preparation at various stages such as phase I, II, and III clinical trials, and has become a domestic leader in microbial expression system CDMO services.
渝公网安备 50011202502165号
